Press Releases

Date Title and Summary Additional Formats
Toggle Summary Marinus Pharmaceuticals to Attend Upcoming Investor Conferences
RADNOR, Pa. , Feb. 07, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that members of its management team will...
View HTML
Toggle Summary Marinus Pharmaceuticals Added to NASDAQ Biotechnology Index
RADNOR, Pa., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that it has been selected for addition to...
View HTML
Toggle Summary Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results
RADNOR, Pa., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and reported its...
View HTML
Toggle Summary Marinus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
RADNOR, Pa., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Edward F....
View HTML
Toggle Summary Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter's option to purchase additional shares
RADNOR, Pa., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") announced the closing of an underwritten public offering of 10,733,334 shares of its common stock for a public offering price of $3.75 per share....
View HTML
Toggle Summary Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
RADNOR, Pa., Sept. 15, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") announced the pricing of an underwritten public offering of 9,333,334 shares of common stock for a public offering price of $3.75 per share....
View HTML
Toggle Summary Marinus Pharmaceuticals Announces Public Offering of Common Stock
RADNOR, Pa., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.  The offering is subject to market conditions, and there can be...
View HTML
Toggle Summary Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone
Substantial and Durable Anti-Seizure Efficacy Shown in Patients Suffering From Severe,  Rare Genetic Epilepsy Marinus to Host Conference Call and Webcast Today at 9:00 am EDT RADNOR, Pa., Sept. 11, 2017 (GLOBE NEWSWIRE) --   Marinus Pharmaceuticals, Inc....
View HTML
Toggle Summary Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2017 Financial Results
Data from Studies in Rare Pediatric Epilepsies and Severe Postpartum Depression Expected in 2 nd Half On-track to Initiate Two Additional Phase 2 Trials Later This Year in Status Epilepticus and Moderate Postpartum Depression RADNOR, Pa., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals,...
View HTML
Toggle Summary FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder
RADNOR, Pa., June 29, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the U.S....
View HTML